Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 10 views
  • 12 May, 2022
  • 99 locations
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

  • 0 views
  • 03 May, 2022
  • 51 locations
Combination of Ranibizumab and Targeted Laser Photocoagulation

Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the

  • 60 views
  • 25 Jan, 2021
  • 8 locations
Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity

(IgG) molecule with slower retinal clearance and therefore prolonged diffusion into the systemic circulation, up to 3 weeks. In contrast, the systemic half-life of a Fab molecule, such as ranibizumab

  • 0 views
  • 09 Sep, 2021
  • 1 location
A Study Of The Response to Treatment After Transition to The Port Delivery System With Ranibizumab [Susvimo (Ranibizumab Injection)] In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab (Belvedere)

treated with anti-VEGF agents other than ranibizumab. The substudy will evaluate the impact on corneal endothelial cells with SUSVIMO refilled every 24 weeks (Q24W) in patients with neovascular age

  • 0 views
  • 21 Apr, 2022
  • 30 locations
A Study to Investigate RO7200220 in Combination With Ranibizumab in Diabetic Macular Edema

pharmacodynamics (PD) of RO7200220 in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one

  • 0 views
  • 22 Apr, 2022
  • 8 locations
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

  • 0 views
  • 23 Jun, 2021
  • 1 location
Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.

neovascularization
ranibizumab
growth factor
monoclonal antibodies
lucentis
  • 0 views
  • 16 May, 2022
  • 39 locations
A Phase 3 Two-part Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

diabetic retinopathy
neovascularization
optical coherence tomography
wet age-related macular degeneration
fundus photography
  • 0 views
  • 10 Mar, 2022
  • 1 location
  • 0 views
  • 11 Mar, 2022
  • 1 location